Addressing population aging and Alzheimer's disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer's Disease Neuroimaging Initiative |
| |
| Authors: | Kathryn A Ellis Christopher C Rowe Victor L Villemagne Ralph N Martins Colin L Masters Olivier Salvado Cassandra Szoeke David Ames |
| |
| Institution: | 1. Department of Psychiatry, Academic Unit for Psychiatry of Old Age, University of Melbourne, Kew, Victoria, Australia;2. Alzheimer''s Disease Clinical Research Group, The Mental Health Research Institute, Parkville, Victoria, Australia;3. Professorial Division, National Ageing Research Institute, Parkville, Victoria, Australia;4. Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, Victoria, Australia;5. Centre of Excellence for Alzheimer''s Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia;6. CSIRO ICT, The Australian e-Health Research Centre–BioMedIA, Herston, Queensland, Australia;7. CSIRO Preventative Health Flagship, Parkville, Victoria, Australia;8. www.aibl.csiro.au;1. Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA;2. Department of Physiology, Pharmacology and Neuroscience, Sophie Davis School of Biomedical Education, City University of New York Medical School, New York, NY, USA;1. UMR1027 Inserm, Toulouse, France;2. University of Toulouse III, Toulouse, France;3. Gerontopole Toulouse, Toulouse University Hospital, Toulouse, France;4. Department of Neurosciences, University of California, San Diego, San Diego, CA, USA;5. CHDI Foundation, Princeton, NJ, USA;6. Janssen AI, South San Francisco, CA, USA;7. Eli Lilly, Indianapolis, IN, USA;8. Department of Psychiatry, Goethe University, Frankfurt, Germany;9. University of Southern California Keck School of Medicine, Los Angeles, CA, USA;10. Center for Imaging of Neurodegenerative Disease, VA Medical Center, University of California San Francisco, San Francisco, CA, USA;11. Alzheimer’s Disease and Memory Disorders Center, Baylor College of Medicine, Houston, TX, USA;12. The Campaign to Prevent Alzheimer’s Disease by 2020, Potomac, MD, USA;13. Bristol-Myers Squibb, Wallingford, CT, USA;14. Global R&D Partners, LLC, San Diego, CA, USA;15. Federal Institute of Drugs and Medical Devices, Bonn, Germany;p. Department of Internal Medicine, Rehabilitation and Geriatrics, University of Geneva, Geneva, Switzerland;q. Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA;r. University of Oxford, Oxford, UK;s. Institute for Memory and Alzheimer’s Disease, UMR-S975, Salpêtrière Hospital, Pierre & Marie Curie University, Paris, France;t. Dementia Research Centre, UCL Institute of Neurology, London, UK;u. Department of Neurology and Alzheimer Center, VU University Medical Centre, Amsterdam, Netherlands;v. University Hospital of Montpellier, Montepellier, France;w. Pentara Corporation, Salt Lake City, UT, USA;x. Alzheimer’s Association, Chicago, IL, USA;1. Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, London, UK;2. Department of Medical Physics and Bioengineering, Translational Imaging Group, Centre for Medical Image Computing, University College London, London, UK;3. Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK;4. Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA;5. Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA;6. Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA;7. Department of Neurology, Butler Hospital, Warren Alpert Medical School, Brown University, Providence, RI, USA;8. Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA;9. Department of Neurology, Columbia University Medical Center, New York, NY, USA;10. Centre of Excellence for Alzheimer''s Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia;11. Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA;12. Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA;13. Department of Radiology and Imaging Sciences, Centre for Neuroimaging, Indiana University School of Medicine, Indianapolis, IN, USA;14. Department of Radiology, Mayo Clinic, Rochester, MN, USA;15. Neuroscience Research Australia, Randwick, NSW, Australia;p. School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia;q. Department of Radiology, School of Medicine, University of California, San Francisco, San Francisco, CA, USA;r. Department of Neurology, Keck USC School of Medicine, Los Angeles, CA, USA;s. Imaging Genetics Center, Stevens Neuroimaging & Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA, USA;t. The Florey Institute, University of Melbourne, Parkville, VIC, Australia;u. Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia;v. Department of Medicine, University of Melbourne, Austin Health, Heidelberg, VIC, Australia;1. School of Psychology and Exercise Science, Murdoch University, Murdoch, Western Australia, Australia;2. Centre of Excellence for Alzheimer''s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia;3. McCusker Alzheimer''s Research Foundation, Nedlands, Western Australia, Australia;4. Division of Biostatistics, Washington University in St Louis, St Louis, Missouri, USA;5. Department of Neurology, Washington University in St Louis, St Louis, Missouri, USA;6. Department of Radiology, Washington University in St Louis, St Louis, Missouri, USA;7. Department of Psychology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA;8. School of Medicine and Pharmacology, University of Western Australia, Crawley, Western Australia, Australia;9. The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia;10. Center for Imaging of Neurodegenerative Disease, San Francisco VA Medical Center, University of California, San Francisco, California, USA;11. Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri, USA;12. Dementia Research Centre, University College London (UCL) Institute of Neurology, London, United Kingdom;13. Department of Neurology, Mayo Clinic Jacksonville, Jacksonville, Florida, USA;14. Department of Neurology, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA;15. German Center for Neurodegenerative Diseases, Munich, Germany;p. Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany;q. German Center for Neurodegenerative Diseases, Tübingen, Germany;r. Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany;s. Department of Neurology, Columbia University Medical Centre, New York, New York, USA;t. Neuroscience Research Australia, Sydney, New South Wales, Australia;u. School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia;1. Department of Health Behavior and Health Education, University of Michigan School of Public Health, Ann Arbor, MI, USA;2. Department of Sociology & Gerontology, Miami University, Oxford, OH, USA |
| |
| Abstract: | The Australian Imaging Biomarkers and Lifestyle (AIBL) study is a longitudinal study of 1112 volunteers from healthy, mild cognitive impairment, and Alzheimer's disease (AD) populations who can be assessed and followed up for prospective research into aging and AD. AIBL aims to improve understanding of the pathogenesis, early clinical manifestation, and diagnosis of AD, and identify diet and lifestyle factors that influence the development of AD. For AIBL, the magnetic resonance imaging parameters of Alzheimer's Disease Neuroimaging Initiative (ADNI) were adopted and the Pittsuburgh compound B (11C-PiB) positron emission tomography (PET) acquisition and neuropsychological tests were designed to permit comparison and pooling with ADNI data. Differences to ADNI include assessment every 18-months, imaging in 25% (magnetic resonance imaging, 11C-PiB PET but no fluorodeoxyglucose PET), more comprehensive neuropsychological testing, and detailed collection of diet and lifestyle data. AIBL has completed the first 18-month follow-up and is making imaging and clinical data available through the ADNI website. Cross-sectional analysis of baseline data is revealing links between cognition, brain amyloid burden, structural brain changes, biomarkers, and lifestyle. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
